Regorafenib in Metastatic Colorectal Cancer: An Exploratory Biomarker Study
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Sep 2017
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Biomarker; Therapeutic Use
- 30 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 30 Mar 2017 Planned End Date changed from 1 Feb 2018 to 1 Dec 2018.
- 30 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Dec 2017.